Introduction {#Sec1}
============

Research into inflammatory disease pathophysiology facilitates the development of increasingly selective pharmaceutical agents that are highly effective but may also be expensive and have serious side effects. Autoinflammation is driven by endogenous danger signals, metabolic mediators, as well as cells and cytokines of the innate immune system, including interleukin (IL)-1, IL-8, and tumor necrosis factor (TNF)-α \[[@CR1]\]. IL-1 is a proinflammatory cytokine that is pathogenically involved in the development of skin diseases. The IL-1 pathway is balanced by activating/promoting agents such as the receptor I (IL-1RI) agonist isoforms IL-1α and IL-1β as well as natural inhibitors of excessive inflammatory responses such as IL-1Ra (a competitive inhibitor of IL-1α and IL-1β) and IL-1RII (which acts as a decoy receptor). While IL-1α initiates the inflammatory process, both isoforms are responsible for propagating and maintaining it \[[@CR2]\].

IL-1 is a proinflammatory cytokine involved in skin homeostasis. In the skin, it is mainly expressed in keratinocytes \[[@CR3]\], but it can also be found in melanocytes, Langerhans cells, and Merkel cells. Two agonist isoforms encoded by genes located at different loci on chromosome 2 target the IL-1 receptor: IL-1α and IL-1β \[[@CR4]\]. These are secreted in the endoplasmic reticulum independently of the Golgi apparatus after inflammasome activation \[[@CR5]\]. The precursor of IL-1α, pro-IL-1α, is biologically active, is expressed more with inflammation, and can reside in the cytoplasm, nucleus, or membrane of a producer cell. The precursor of IL-1β, pro-IL-1β, is biologically inactive until processed by intracellular caspase-1 in inflammasomes or by extracellular neutrophilic proteases such as elastase, chymase, granzyme A, cathepsin G, and proteinase \[[@CR6]\]. IL-1 has two receptors: IL-1RI and IL-1RII. Signal transduction caused by IL-1 occurs exclusively through IL-1RI. IL-1α, IL-1β, and extracellular pro-IL-1α inhibit IL-1RI with the same affinity. Signal transduction is initiated by IRAK activation, which in turn activates transcription factors such as nuclear factor kappa B (NF-κB), c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase (JNK-MAPK) signaling \[[@CR7]\]. There are natural inhibitors of excessive inflammatory responses such as IL-1Ra and IL-1RII. IL-1Ra acts as a competitive inhibitor of IL-1α and IL-1β and exists in two isoforms: the soluble glycosylated extracellular isoform (sIL-1Ra), which is predominantly produced by activated macrophages and monocytes, and the nonglycosylated intracellular isoform (icIL-1Ra), which is produced mainly by Kupffer cells \[[@CR8]\]. The nonglycosylated isoform regulates intracellular IL-1-dependent responses. IL-1RII functions as a decoy receptor since it lacks a Toll/IL-1R (TIR) domain \[[@CR9]\].

With respect to their biological functions, IL-1 isoforms are generally active during stress responses, inflammation onset, and immune response activation, and they partake in gene expression regulation. They also intervene in carcinogenesis and tumor progression by regulating angiogenesis. These functions can be performed selectively by one isoform alone or can be initiated by one isoform and perpetuated by another, exerting effects at the local (IL-1α) or systemic (IL-1β) level \[[@CR10]\]. The regulation of IL-1 can be affected by different factors, both genetic and acquired. Genetic factors include mutations such as IL-1β 511 (CT) polymorphism, IL-1α-889 (C → T) polymorphism, and melanocortin 1 receptor (MC1R) gene polymorphism. These can result in differences in immune response or susceptibility to different diseases. Alternatively, ultraviolet radiation A and B, human papillomavirus infection, skin barrier integrity alteration, and exposure to certain chemicals have been found to be related to dysregulation of the IL-1 pathway \[[@CR4]\].

IL-1 pathway alterations have been associated with the onset and progression of several dermatological diseases, including psoriasis \[[@CR11]\], atopic dermatitis \[[@CR12]\], neutrophilic diseases (e.g., Sjögren's syndrome, pyoderma gangrenosum, Sweet syndrome, or subcorneal pustular dermatosis) \[[@CR13]\], as well as the development of neoplastic diseases such as actinic keratosis, Bowen's disease, cutaneous epidermoid carcinoma, or melanoma \[[@CR14]\]. Research conducted regarding the pathophysiological mechanisms for these diseases has led to the development of selective pharmaceutical agents such as anakinra (a recombinant IL-1Ra that competes with IL-1R agonists for its receptor), rilonacept (which acts as a soluble decoy preventing the activation of IL-1RI \[[@CR15]\]), canakinumab (a human monoclonal antibody targeting IL-1β \[[@CR16]\]), or, more recently, MABp1 (an anti-IL-1α monoclonal antibody \[[@CR17]\]). However, given the broad expression and systemic functions of IL-1β and IL-1R, it is questionable whether the long-term effects of these drugs are tolerable. Another drawback of these inhibitors is that they have been associated with bacterial infections, thus limiting their use. From this perspective, anti-IL-1α may have a clinical advantage since they are applied locally rather than systemically, thus potentially limiting adverse effects \[[@CR10]\].

The available evidence on the use of IL-1 pathway-modulating agents for the treatment of dermatological diseases is scarce but growing. However, while randomized clinical trials currently represent the best source of evidence, they are not always available, thus making it necessary to obtain secondary evidence. Integrating the optimal research evidence available with clinical experience and patient values has been shown to improve care, health, and cost outcomes \[[@CR18]\]. This is likely because evidence-based guidelines rank interventions based on cost-effectiveness, which allows us to discard ineffective alternatives, improve patient status over the long term, avoid complications and additional treatments, and identify measures for disease prevention. Thus, it is necessary to scientifically synthesize the breadth of studies derived from primary research. The secondary scientific research methodology applied depends on the type of research question being asked and the urgency of the response \[[@CR19]\]. They can be divided into the following categories: (1) systematic reviews, which question the effectiveness of an intervention; (2) rapid reviews, when time is a critical factor; (3) scoping reviews, which provide an overview of a broad field; and (4) realistic reviews, which are designed to determine how and why complex social interventions function. Specifically, a scoping review is a form of scientific synthesis that addresses an exploratory research question aimed at mapping key concepts and identifying research gaps related to a defined area or field by systematically searching, selecting, and synthesizing existing knowledge \[[@CR20]\]. These studies aim to synthesize and present the available evidence, to identify and make recommendations about specific areas of research, and finally to explore the possibility of carrying out systematic reviews on the specific questions formulated.

Here, we aimed to establish a methodology for broadly synthesizing the available evidence on the indications for and the mechanisms of action, efficacies, and safety of IL-1 pathway-targeting drugs that are used to treat dermatological diseases.

Methods {#Sec2}
=======

Protocol Design {#Sec3}
---------------

The aim of the study was to devise a protocol for broadly addressing the published evidence on IL-1-targeted drugs used in the treatment of dermatological diseases, with three goals in mind: to qualitatively synthesize the available data, to explore the opportunity to formulate questions that could be answered by performing systematic reviews, and to identify gaps in the existing literature. To achieve this aim, we used an existing methodology for conducting scoping reviews \[[@CR21]\] that can be broken down into five stages (Table [1](#Tab1){ref-type="table"}): (1) identify the research question; (2) identify the relevant studies; (3) select the studies; (4) chart the data; and (5) collate, summarize, and report the results, and---optionally---perform a consultation exercise. Any necessary alterations to this methodology will be outlined in the Results section of the scoping review.Table 1Stages of the scoping review1. Identifying the research question1.1. Overarching goalTo explore the depth and breadth of evidence for the indications for and the mechanisms of action, efficacies, and safety of drugs that act on interleukin-1 in the treatment of patients with dermatological diseases1.2. Research questionWhat are the indications for and the mechanisms of action, efficacies, and safety of drugs that act on interleukin-1 in the treatment of dermatological diseases?1.3. Purposes of this scoping review1.3.1. Review the evidence for the indications for drugs that act on interleukin-1 in the treatment of dermatogical diseases1.3.2. Review the evidence for the mechanisms of action of drugs that act on interleukin-1 in the treatment of dermatogical diseases1.3.3. Review the evidence for the efficacies of the drugs that act on interleukin-1 in the treatment of dermatogical diseases1.3.4. Review the evidence for the safety of drugs that act on interleukin-1 in the treatment of dermatogical diseases1.3.5. Review the evidence for the costs of drugs that act on interleukin-1 in the treatment of dermatogical diseases1.3.6. Obtain concrete research questions that can be answered by performing systematic reviews1.3.7. Identify research gaps in the existing literature2. Identifying relevant literature2.1. We will perform a three-step search:2.1.1. First search---an initial limited search of the MEDLINE and EMBASE databases to find keywords in the title, abstract, and the index terms used to describe the articles2.1.2. Second search---a search of MEDLINE and EMBASE using all identified keywords2.1.3. Third search---the reference lists of all identified reports and articles are searched for additional studies2.2. We will include the studies published in full in English until March 20182.3. We will contact the authors of primary studies or reviews for further information if this is relevant2.4. The process of searching and selecting will be carried out by at least two reviewers; any disagreement between them will be resolved by referring to a third reviewer3. Selecting the studies3.1. Inclusion criteria3.1.1.We will include in the review published studies of interleukin-1 treatments that describe indications, mechanisms of action, efficacies, safety, and costs3.1.2. Study designs: we will include guidelines, systematic reviews, observational studies, cross-sectional case reports, series, and expert opinions3.2. Exclusion criteria3.2.1. We will exclude narrative reviews and studies done in vitro or in animals4. Charting the data4.1. We will extract the data in a predefined form4.2. From each study, we will extract the title, objective, and the main variables relating to patient, intervention, comparator, outcome (efficacy and safety), and bibliographic data. We will classify the studies by treatment indication4.3. The list of studies, variables, and data of the review will be published in an online file4.2. Data will be collected by at least two reviewers; any disagreement between them will be resolved by referring to a third reviewer5. Collating, summarizing, and reporting results5.1. The results of the comprehensive search will be presented using a PRISMA flow diagram5.2. We will qualitatively synthesize the evidence obtained, categorizing it by topic into indications, mechanisms of action, efficacies, and safety of drugs that act on interleukin-1 in the treatment of dermatological diseases, and we will present it in a diagrammatic tabular form and in a descriptive format

Inclusion Criteria {#Sec4}
------------------

We used the mnemonic "PCC" (participants, concept, context) to define the inclusion criteria.

Participants {#Sec5}
------------

The review should include all patients with dermatological diseases that could potentially be treated using IL-1-targeting drugs. No restrictions concerning age, ethnicity, study design, or any other characteristic should be imposed.

Concept {#Sec6}
-------

The existing literature on the usage of IL-1-targeting drugs in the treatment of dermatological diseases should be reviewed, focusing on indications, mechanisms of action, efficacies, safety, and costs.

Context {#Sec7}
-------

The context of the review should not be limited to a particular setting or country.

Research Question {#Sec8}
-----------------

The research question to be asked is: 'What are the indications for and the mechanisms of action, efficacies, and safety of IL-1-targeting drugs used in the treatment of dermatological diseases?'

Identifying Relevant Literature {#Sec9}
-------------------------------

A three-step literature search should be performed to identify and locate all relevant studies. The first step will entail a limited search of the MEDLINE and EMBASE databases. This will be followed by a keyword analysis of the titles, abstracts, and indexing categorizations used. The second step will be a second search of those two databases using the newly identified keywords and indexing terms. The third and final step will involve searching the reference lists of all the identified reports and articles for additional studies. Where necessary, authors of primary studies or reviews should be contacted for additional information. Due to time and funding limitations, only studies published in English prior to March 2018 will be included. The literature search and review should be carried out by at least two researchers.

Identifying Relevant Studies {#Sec10}
----------------------------

The inclusion criteria listed previously will be applied to the literature in order to select relevant studies. This process should be carried out by at least two researchers.

Data Charting {#Sec11}
-------------

The following relevant data should be recorded and charted: (a) author(s), (b) year of publication, (c) origin (where the study was published or conducted), (d) aims/purpose, (e) study population and sample size (if applicable), (f) methodology, (g) intervention type and comparator (with applicable details), (h) intervention duration (if applicable), (i) outcomes (with applicable details such as measurement criteria), and (j) key findings related to the scoping review question.

Data collection should be performed by at least two reviewers.

Collating, Summarizing, and Reporting Results {#Sec12}
---------------------------------------------

The PCC inclusion criteria will guide data presentation. First, search results will be presented in a PRISMA flow chart. Subsequently, extracted data will be categorized into topics such as mechanism of action, efficacy, safety, and cost. A clear explanation of each reported category should be provided. Scoping review results will be presented in diagrammatic (e.g., a map), tabular, and descriptive formats. A narrative summary will accompany the tabulated and/or charted results and will describe how the results relate to the review objective and question(s).

Compliance with Ethics Guidelines {#Sec13}
---------------------------------

This protocol relates to a search for previously conducted studies, and does not involve any new human or animal subjects performed by the authors.

Conclusions {#Sec14}
===========

We have presented our protocol for systematically conducting a scoping review to broadly synthesize the available evidence on the indications for and the mechanisms of action, efficacies, and safety of interleukin-1 pathway-targeting drugs that are used to treat dermatological diseases. Evidence-based medicine is intended to optimize decision-making by emphasizing the use of evidence derived from well-designed and well-conducted research. Currently, most reviews of anti-IL-1 treatments are narrative reviews which lack the necessary methodological detail to promote reproducibility and reduce the risk of bias. Secondary research methodologies are constantly being developed and must be adapted to the type of research question being asked and the urgency with which the question must be answered. We believe that the scoping review methodology is the one that is best suited to the question posed in this study. The results will provide unique insights into the available evidence on the use of IL-1-targeting drugs in the treatment of dermatological diseases, facilitating the detection of knowledge gaps and the identification of new questions to address via additional systematic reviews.
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